65,437 trials
Bladder Urothelial Carcinoma · Stage I Bladder Cancer AJCC v6 and v7 · Stage II Bladder Cancer AJCC v6 and v7
Primary: Acute Treatment-related Toxicity — 7; 14 participants
Prostate Cancer
Primary: Percentage of Participants With Prostate-specific Antigen (PSA) Response — 42.7 Percentage of participants
Macular Edema (ME)
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye — 5.7; 2.9 letters — p=0.0111
Cancer
Primary: Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib — 23.6; 30.7; 30.5; 20.5 micromolar
Osteoarthritis
Primary: Change From Baseline in the Brief Pain Inventory (BPI) 24-hour Average Pain Score — -2.23; -1.73 units on a scale
Cystic Fibrosis
Primary: The Use of the Approved US TOBI Podhaler Instructions for Use (IFU) to Communicates the Information Necessary to Achieve Safe and Effective Use of the Podhaler Device…
Human Immunodeficiency Virus (HIV) · HIV Associated Neurocognitive Disorders (HAND)
Primary: Change in Neurocognitive Functioning — -0.94; -0.81; -1.03; -0.51 Global Neurocognitive Z-Score — p=0.05
Healthy
Primary: AUCt for Serum Deferiprone and Deferiprone 3-O-glucuronide — 63.5; 52.3; 71.1; 171.9 mcg*h/mL
Hepatitis C · Depression · PTSD
Primary: Sustained Viral Response (SVR) — 30; 12.8 percentage of Participants — p=0.07
Skin and Subcutaneous Tissue Fungal Infections
Primary: The Prevalence of Superficial and Cutaneous Fungal Infections Among Drug and Non-Drug Users — 73; 62 participants
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024
Airway Obstruction
Primary: Changes in Lung Function Measurements During One Work Shift (6-8h) — 4.99; 3.88 Litres
Analgesia, Obstetrical · Cesarean Section
Primary: Dose of IT Morphine and IT Hydromorphone for Adequate Analgesia (Pain Score Less Than or Equal to 3) in 90% of Patients — 75; 150 micrograms
Allergic Conjunctivitis
Primary: Ocular Itching — 1.27; 1.57; 1.16; 1.88 units on a scale
Acute Leukemias
Primary: Rate of Complete Remission (CR) — 0; 0 Participants